Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Ovarian Cancer Market Report Overview
The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan.
Ovarian cancer is one of the most lethal gynecological cancers worldwide. Approximately 90% of ovarian cancer cases are epithelial, with distinct sites of origin arising from the ovarian surface epithelium or distal fallopian epithelium. Each year in the US, more than 19,700 women receive a new diagnosis of ovarian cancer.
Ovarian Cancer Market Outlook 2022-2032 ($ Billion)
Buy the Full Report to Know More About the Ovarian Cancer Market Forecast
Download a Free Sample Report
The ovarian cancer market research report offers an overview of ovarian cancer, including its epidemiology, symptoms, diagnosis, and disease management. The report covers key topics, including strategic competitor assessment and market characterization that will help in identifying smart business strategies. In addition, the report’s data on unmet needs and clinical trial mapping will assist in understanding market gaps and making actionable predictions.
Market Size (2022) | $3.3 billion |
CAGR (2022-2032) | >1% |
Key Countries (7MM) | · The US
· 5EU · Japan |
Key Drug Classes | · PARP Inhibitors
· Chemotherapy · Hormonal Therapy · Targeted Therapy · VEGF Inhibitor |
Key Sponsors | · National Cancer Institute, The US
· AstraZeneca · Incyte Corp · Tesaro Inc · Pfizer Inc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Ovarian Cancer Market Dynamics
The rising sales of ImmunoGen’s Elahere is one of the most impactful drivers of growth for the ovarian cancer market. Elahere is anticipated to launch in the 5EU and Japan during the forecast period. However, Factors such as high costs associated with treatments hamper the market growth in the forecast period.
Buy the Full Report for Additional Insights on the Key Ovarian Cancer Market Dynamics
Download a Free Sample Report
Ovarian Cancer Market Segmentation by Country
The key countries in the ovarian cancer market are the US, 5EU, and Japan. In 2022, the US dominated the total ovarian cancer market share. The dominance of the US within the 7MM is due to its larger population suffering from ovarian cancer and higher drug prices in the country.
Ovarian Cancer Market Analysis by Country, 2022 (%)
Buy the Full Report for Country-Wise Insights on the Ovarian Cancer Market
Download a Free Sample Report
Ovarian Cancer Market Segmentation by Drug Classes
During 2022, there were several drug classes in the ovarian cancer market including PARP inhibitors, chemotherapy, hormonal therapy, targeted therapy, and VEGF inhibitor among others. In 2022, PARP inhibitors contributed the highest sales to the ovarian cancer market.
Ovarian Cancer Market Analysis by Drug Classes, 2022 (%)
Buy the Full Report for Drug-Class Insights on the Ovarian Cancer Market
Download a Free Sample Report
Ovarian Cancer Market Segmentation by Sponsors
The key sponsors in the ovarian cancer market are the National Cancer Institute, The US, AstraZeneca, Incyte Corp, Tesaro Inc., and Pfizer Inc. among others. Lynparza’s manufacturer, AstraZeneca, has been a leading sponsor of clinical trials in ovarian cancer.
Ovarian Cancer Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for Sponsor-Wise Insights on the Ovarian Cancer Market
Download a Free Sample Report
Segments Covered in this Report
Ovarian Cancer Market Country Outlook ($ Billion, 2022-2032)
- The US
- 5EU
- Japan
Ovarian Cancer Market Drug Classes Outlook (%, 2022-2032)
- PARP Inhibitors
- Chemotherapy
- Hormonal Therapy
- Targeted Therapy
- VEGF Inhibitor
Scope
- Overview of Ovarian Cancer, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized Ovarian Cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Ovarian Cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Ovarian Cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global Ovarian Cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
Report deliverables include a PowerPoint report and Excel-based forecast model
Forecast includes 7 countries
Forecast covers 2022-2032
Reasons to Buy
- Review the pipeline products and technologies and identify the companies with the most robust pipeline to develop and design your in-licensing and out-licensing strategies.
- Understand the trends shaping and driving the ovarian cancer therapeutics market to develop business strategies.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Alkermes
AstraZeneca Plc
Bristol Myers Squibb
Clovis Oncology
Corcept Therapeutics
Eisai
Genentech
Genelux Corp
GlaxoSmithKline
Merck & Co
Mersana Therapeutics
OncoQuest Inc
Ono Pharmaceuticals
Roche
Sutro Biopharma Inc
Verastem Oncology
Zentalis Pharmaceuticals
Table of Contents
Frequently asked questions
-
What was the ovarian cancer market size in 2022?
The ovarian cancer market in the seven major markets was $3.3 billion in 2022.
-
What will the ovarian cancer market CAGR be during 2022-2032?
The ovarian cancer market will register a CAGR of more than 1% from 2022 to 2032 in the seven major markets (7MM).
-
Which was the leading country in the 7MM in the ovarian cancer market in 2022?
In 2022, the US dominated the total ovarian cancer market in the 7MM.
-
Which was the leading drug class in the ovarian cancer market in 2022?
In 2022, the PARP inhibitors drug class contributed the highest sales to the ovarian cancer market.
-
Which are the leading sponsors in the ovarian cancer market?
The key sponsors in the ovarian cancer market are the National Cancer Institute, The US, AstraZeneca, Incyte Corp, Tesaro Inc., and Pfizer Inc. among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.